Perspective Therapeutics partners with Merck to test [212Pb]PSV359 with Keytruda in FAP-α-positive solid tumors

Reuters2026/09/14 10:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck to test [212Pb]PSV359 with Keytruda (pembrolizumab).
Combination will be evaluated via an amendment to Perspective’s ongoing Phase 1/2a study in FAP-α-positive non-small cell lung cancer and colorectal cancer.
Merck will supply pembrolizumab at no cost; Perspective will sponsor the trial.
Study has completed enrollment in the first three monotherapy dose cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140616PRIMZONEFULLFEED9825542) on September 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Perspective Therapeutics partners with Merck to test [212Pb]PSV359 with Keytruda in FAP-α-positive solid tumors

You may also like

Crypto prices